Ensysce Biosciences (ENSC) Net Cash Flow (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Net Cash Flow of -$414714.0 for Q3 2025, down 113.33% year-over-year from $3.1 million in Q3 2024, and up 50.68% quarter-over-quarter from -$840916.0 in Q2 2025.
Ensysce Biosciences (ENSC) Net Cash Flow (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Net Cash Flow for 8 consecutive years, with -$414714.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Cash Flow fell 113.33% year-over-year to -$414714.0; the TTM figure through Dec 2025 stood at -$1.7 million (down 171.69% YoY), while the FY2024 annual figure was $2.4 million, up 217.51% from the prior year.
- Net Cash Flow rose to -$414714.0 in Q3 2025 per ENSC's latest filing, from -$840916.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $7.7 million in Q2 2021 and bottomed at -$4.7 million in Q2 2022.
- Historically, Net Cash Flow has averaged $81060.4 across 5 years, with a median of -$449586.0 in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 11612.91% — and 2024, when it soared 231.69%.
- Ensysce Biosciences' Net Cash Flow stood at $5.4 million in 2021, then slumped by 125.01% to -$1.4 million in 2022, then soared by 74.86% to -$340777.0 in 2023, then slumped by 91.19% to -$651515.0 in 2024, then jumped by 36.35% to -$414714.0 in 2025.
- Business Quant data shows ENSC's Net Cash Flow at -$414714.0 in Q3 2025, -$840916.0 in Q2 2025, and -$449586.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -414,714.00 |
| Sep 30, 2025 | -414,714.00 |
| Jun 30, 2025 | -840,916.00 |
| Jun 30, 2025 | -840,916.00 |
| Mar 31, 2025 | -449,586.00 |
| Mar 31, 2025 | -449,586.00 |
| Dec 31, 2024 | -651,515.00 |
| Dec 31, 2024 | -651,515.00 |
| Sep 30, 2024 | 3.11 Mn |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | -340,777.00 |
| Dec 31, 2023 | -340,777.00 |
| Sep 30, 2023 | -2.37 Mn |
| Sep 30, 2023 | -2.37 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Jun 30, 2023 | 2.41 Mn |